Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BPH
MCID: PRS129
MIFTS: 48

Prostatic Hyperplasia, Benign (BPH)

Categories: Endocrine diseases, Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Prostatic Hyperplasia, Benign

About this section

MalaCards integrated aliases for Prostatic Hyperplasia, Benign:

Name: Prostatic Hyperplasia, Benign 57
Benign Prostatic Hyperplasia 54 17 70
Prostatic Hyperplasia 70
Bph 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
prostatic hyperplasia, benign:
Inheritance autosomal dominant inheritance
Onset and clinical course infantile onset


Classifications:

MalaCards categories:
Anatomical: Nephrological diseases Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 600082
MedGen 41 C1704272
SNOMED-CT via HPO 68 263681008 266569009
UMLS 70 C1704272 C2937421
Sources

Summaries for Prostatic Hyperplasia, Benign

About this section
OMIM® : 57 Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth of the prostate gland, and is histologically defined as hyperplasia of the prostate gland. BPH is an age-related phenomenon in men beginning at about age 40 years. BPH may result in prostatic enlargement and clinical symptoms most commonly affecting the lower urinary tract. These symptoms may be obstructive, including hesitancy, weak flow, and urinary retention, or irritative, including increased frequency and urgency. However, not all men with histologic BPH will develop prostatic enlargement or urinary symptoms (review by Roehrborn, 2005). (600082) (Updated 05-Apr-2021)

MalaCards based summary : Prostatic Hyperplasia, Benign, also known as benign prostatic hyperplasia, is related to alopecia and sexual disorder, and has symptoms including prostatism An important gene associated with Prostatic Hyperplasia, Benign is SRD5A1 (Steroid 5 Alpha-Reductase 1), and among its related pathways/superpathways are Translation Non-genomic (rapid) action of Androgen Receptor and Coregulation of Androgen receptor activity. The drugs Diclofenac and Silodosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, smooth muscle and bone, and related phenotypes are benign prostatic hyperplasia and Decreased caspase 3/7 activity

Wikipedia : 73 Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size... more...

Sources

Related Diseases for Prostatic Hyperplasia, Benign

About this section

Diseases related to Prostatic Hyperplasia, Benign via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
# Related Disease Score Top Affiliating Genes
1 alopecia 30.9 SRD5A2 SRD5A1 AR
2 sexual disorder 30.9 PDE5A KLK3 AR
3 alopecia, androgenetic, 1 30.7 SRD5A2 SRD5A1 AR
4 neurogenic bladder 30.6 PDE5A KLK3
5 prostatic acinar adenocarcinoma 30.3 KLK3 AR
6 bladder neck obstruction 30.3 PDE5A KLK3
7 urethral stricture 30.2 PDE5A KLK3 FOLH1
8 impotence 30.1 SRD5A1 PDE5A KLK3
9 pseudohermaphroditism 30.0 SRD5A2 SRD5A1 AR
10 hypospadias 30.0 SRD5A2 SRD5A1 AR
11 cryptorchidism, unilateral or bilateral 29.9 SRD5A2 SRD5A1 AR
12 androgenic alopecia 29.9 SRD5A2 SRD5A1 KLK3 FGF7 AR
13 premature ejaculation 29.9 PDE5A AR
14 prostatic adenoma 29.9 SRD5A1 SERPINA3 KLK3 AR ACP3
15 prostate disease 29.8 SRD5A2 SRD5A1 SERPINA3 PCA3 KLK3 KLK2
16 prostatitis 29.6 SERPINA3 PDE5A PCA3 KLK3 ADRA1A ACP3
17 gynecomastia 29.6 SRD5A2 SRD5A1 KLK3 AR
18 suppression of tumorigenicity 12 29.4 SERPINA3 KLK3 FOLH1 AR
19 prostatic hypertrophy 29.2 SRD5A2 SRD5A1 SERPINA3 KLK3 AR ADRA1A
20 prostate cancer 27.6 SRD5A2 SRD5A1 SERPINA3 PCA3 KLK3 KLK2
21 adenocarcinoma 10.6
22 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.5
23 b-cell lymphoma 10.5
24 insulin-like growth factor i 10.5
25 kidney disease 10.5
26 chronic kidney disease 10.4
27 proteasome-associated autoinflammatory syndrome 1 10.4
28 urolithiasis 10.3
29 bacteriuria 10.3
30 liver cirrhosis 10.3
31 low compliance bladder 10.3
32 pulmonary disease, chronic obstructive 10.3
33 non-alcoholic fatty liver disease 10.3
34 dementia 10.3
35 liver disease 10.3
36 fatty liver disease 10.3
37 urinary tract infection 10.3
38 prostate adenoid cystic carcinoma 10.3 KLK3 AR
39 female stress incontinence 10.3 PDE5A KLK3
40 prostate leiomyoma 10.3 KLK3 AR
41 anxiety 10.3
42 rickets 10.3
43 pyuria 10.3
44 prostate calculus 10.3 KLK3 AR
45 nodular prostate 10.3 KLK3 AR
46 nephrogenic adenoma of the urethra 10.2 KLK3 ACP3
47 bronchiectasis 3 10.2 KLK3 AR
48 androgen insensitivity, partial 10.2 SRD5A1 AR
49 pre-eclampsia 10.2
50 hermaphroditism 10.2 SRD5A2 AR

Graphical network of the top 20 diseases related to Prostatic Hyperplasia, Benign:



Diseases related to Prostatic Hyperplasia, Benign
Sources

Symptoms & Phenotypes for Prostatic Hyperplasia, Benign

About this section

Human phenotypes related to Prostatic Hyperplasia, Benign:

31
# Description HPO Frequency HPO Source Accession
1 benign prostatic hyperplasia 31 HP:0008711

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
G U:
benign prostatic hyperplasia

Misc:
early age of onset

Clinical features from OMIM®:

600082 (Updated 05-Apr-2021)

UMLS symptoms related to Prostatic Hyperplasia, Benign:


prostatism

GenomeRNAi Phenotypes related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased caspase 3/7 activity GR00318-A 8.8 ACP3 AR PDE5A
Sources

Drugs & Therapeutics for Prostatic Hyperplasia, Benign

About this section

Drugs for Prostatic Hyperplasia, Benign (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Silodosin Approved Phase 4 160970-54-7
3
Saw palmetto Approved, Experimental, Investigational Phase 4
4
Testosterone Approved, Investigational Phase 4 58-22-0 6013
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
carbamide peroxide Approved Phase 4 124-43-6
8
Methyltestosterone Approved Phase 4 58-18-4 6010
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Testosterone enanthate Approved Phase 4 315-37-7 9416
11
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
12
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
13
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
14
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
15
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
16
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
17
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
21
Mirabegron Approved Phase 4 223673-61-8 9865528
22
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
23
Dutasteride Approved, Investigational Phase 4 164656-23-9 6918296 152945
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
27
Naftopidil Investigational Phase 4 57149-07-2
28 5-alpha Reductase Inhibitors Phase 4
29 Cholinergic Agents Phase 4
30 Saw palmetto extract Phase 4
31 Androgens Phase 4
32 Anesthetics, Local Phase 4
33 Solifenacin succinate Phase 4 242478-38-2
34 Muscarinic Antagonists Phase 4
35 Cholinergic Antagonists Phase 4
36 Anti-Infective Agents Phase 4
37 Citrate Phase 4
38 Sildenafil Citrate Phase 4 171599-83-0
39 Mitogens Phase 4
40 Antibiotics, Antitubercular Phase 4
41 Anti-Bacterial Agents Phase 4
42 calcium channel blockers Phase 4
43 Calcium, Dietary Phase 4
44
Bilirubin Phase 4 635-65-4 5280352
45 N-Methylaspartate Phase 4
46 Testosterone 17 beta-cypionate Phase 4
47 Tolterodine tartrate Phase 4 124937-52-6
48 Endothelial Growth Factors Phase 4
49 Anti-Arrhythmia Agents Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 527)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Unknown status NCT02443844 Phase 4 Tamsulosin
3 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
4 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
5 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
6 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
7 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
8 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
9 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
10 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
11 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
12 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
13 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Unknown status NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
14 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
15 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
16 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
17 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
18 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
19 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
20 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
21 Benign Prostatic Hyperplasia and Ischemic Heart DIsease Completed NCT03856242 Phase 4 Tamsulosin Oral Capsule
22 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
23 The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
24 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
25 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
26 A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
27 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Completed NCT02757768 Phase 4 Mirabegron;Placebo;Tamsulosin Hydrochloride
28 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
29 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
30 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
31 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
32 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
33 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
34 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
35 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
36 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Completed NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
37 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
38 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
39 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Completed NCT02034604 Phase 4 Naftofidil;Tamsulosin
40 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
41 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
42 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
43 The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility Completed NCT00836823 Phase 4 Alfuzosin
44 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction: A 24-Week Open-Label, Single-Arm Pilot Study Completed NCT00827814 Phase 4 Dutasteride
45 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
46 Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
47 Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH Completed NCT00701779 Phase 4 Tamsulosin
48 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
49 An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg Completed NCT02180789 Phase 4 Tamsulosin OCAS
50 A Randomized, Double-blind, Placebo-controlled, Study of Safety and Efficacy of Dutasteride in Combination With Tolterodine ER or Placebo in Men With Lower Urinary Tract Symptoms (LUTS) Including Urgency and Frequency Completed NCT00939120 Phase 4 Tolterodine ER 4mg;Placebo;Pre-randomization Dutasteride

Search NIH Clinical Center for Prostatic Hyperplasia, Benign

Inferred drug relations via UMLS 70 / NDF-RT 51 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride
Sources

Genetic Tests for Prostatic Hyperplasia, Benign

About this section
Sources

Anatomical Context for Prostatic Hyperplasia, Benign

About this section

MalaCards organs/tissues related to Prostatic Hyperplasia, Benign:

40
Prostate, Smooth Muscle, Bone, Endothelial, Kidney, Liver, Testis
Sources

Publications for Prostatic Hyperplasia, Benign

About this section

Articles related to Prostatic Hyperplasia, Benign:

(show top 50) (show all 14168)
# Title Authors PMID Year
1
A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. 61 57
17222644 2007
2
Benign prostatic hyperplasia: an overview. 57 61
16985902 2005
3
Genetic susceptibility of benign prostatic hyperplasia. 57 61
7515446 1994
4
Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. 54 61
20467844 2010
5
Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. 61 54
20054821 2010
6
Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia. 54 61
19690867 2010
7
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. 61 54
20303529 2010
8
Extracellular matrix associated protein CYR61 is linked to prostate cancer development. 54 61
20172544 2010
9
Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. 61 54
20398021 2010
10
Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. 54 61
19854485 2010
11
Silodosin for benign prostatic hyperplasia. 54 61
20071497 2010
12
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. 54 61
19796053 2010
13
DD3(PCA3) gene expression in cancer and prostatic hyperplasia. 61 54
20003831 2009
14
Prostasin regulates iNOS and cyclin D1 expression by modulating protease-activated receptor-2 signaling in prostate epithelial cells. 61 54
19670249 2009
15
Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. 54 61
19443907 2009
16
Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. 61 54
19757985 2009
17
Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. 54 61
19697101 2009
18
TRPV6 alleles do not influence prostate cancer progression. 61 54
19857260 2009
19
Men's sexual health: evaluating the effectiveness of print- and PDA-based CME. 54 61
19453917 2009
20
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? 54 61
19239452 2009
21
Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. 54 61
19428074 2009
22
Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. 61 54
19517319 2009
23
CYP17 gene polymorphism and its association in north Indian prostate cancer patients. 61 54
19443382 2009
24
[Expression of estrogen receptor beta in benign prostatic hyperplasia complicated by chronic prostatitis]. 54 61
19472903 2009
25
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. 54 61
19021615 2009
26
The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. 54 61
19107880 2009
27
Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. 61 54
19193422 2009
28
[Medical combination therapy in LUTS suggestive of BPH]. 54 61
19212753 2009
29
Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status. 54 61
19180570 2009
30
The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. 54 61
19084862 2009
31
Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. 54 61
18929399 2009
32
The role of combination medical therapy in benign prostatic hyperplasia. 61 54
19002123 2008
33
Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. 61 54
18761597 2008
34
Association between 5-alpha reductase inhibition and risk of hip fracture. 61 54
18840839 2008
35
Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. 54 61
18692876 2008
36
Joint effects of inflammation and androgen metabolism on prostate cancer severity. 54 61
18566991 2008
37
The effect of 5 alpha-reductase inhibitors on erectile function. 61 54
18421068 2008
38
Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. 61 54
18495332 2008
39
Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia. 54 61
18773737 2008
40
Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. 54 61
18837951 2008
41
Protease-activated receptor-1 upregulates fibroblast growth factor 7 in stroma of benign prostatic hyperplasia. 61 54
18386288 2008
42
Combination 5-alpha-reductase inhibitors and alpha-blockers for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. 61 54
18765128 2008
43
Interactive spaced education versus web based modules for teaching urology to medical students: a randomized controlled trial. 54 61
18423715 2008
44
Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia. 54 61
20029472 2008
45
A role for the androgen-receptor in clinically localized and advanced prostate cancer. 54 61
18471792 2008
46
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. 54 61
18471794 2008
47
Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. 54 61
18342171 2008
48
The role of estrogens and estrogen receptors in normal prostate growth and disease. 61 54
18093629 2008
49
Doxazosin in the current treatment of hypertension. 54 61
18312163 2008
50
Persistent prostatic hematuria. 54 61
18253111 2008
Sources

Variations for Prostatic Hyperplasia, Benign

About this section
Sources

Expression for Prostatic Hyperplasia, Benign

About this section
Search GEO for disease gene expression data for Prostatic Hyperplasia, Benign.
Sources

Pathways for Prostatic Hyperplasia, Benign

About this section

Pathways related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 11.58 SRD5A2 SRD5A1 KLK3 AR
2
Coregulation of Androgen receptor activity 1
11.09 KLK3 KLK2 AR
3
superpathway of steroid hormone biosynthesis 1
Show member pathways
 10.64 SRD5A2 SRD5A1
4
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 65
10.58 KLK3 KLK2
5
Regulation of Androgen receptor activity 1
10.5 KLK3 KLK2 AR
Sources

GO Terms for Prostatic Hyperplasia, Benign

About this section

Biological processes related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.8 KLK3 KLK2 HPN FOLH1
2 cell-cell signaling GO:0007267 9.65 SRD5A2 AR ADRA1A
3 male gonad development GO:0008584 9.5 SRD5A2 SRD5A1 AR
4 sex differentiation GO:0007548 9.46 SRD5A2 SRD5A1
5 zymogen activation GO:0031638 9.43 KLK3 KLK2
6 male genitalia development GO:0030539 9.4 SRD5A2 SRD5A1
7 androgen metabolic process GO:0008209 9.37 SRD5A2 SRD5A1
8 androgen biosynthetic process GO:0006702 9.26 SRD5A2 SRD5A1
9 cellular response to testosterone stimulus GO:0071394 9.16 SRD5A1 AR
10 pilomotor reflex GO:0097195 8.96 HPN ADRA1A
11 regulation of systemic arterial blood pressure GO:0003073 8.8 KLK3 KLK2 AR

Molecular functions related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.8 PDE5A KLK3 KLK2 HPN FOLH1 ACP3
2 peptidase activity GO:0008233 9.71 KLK3 KLK2 HPN FOLH1
3 serine-type endopeptidase activity GO:0004252 9.43 KLK3 KLK2 HPN
4 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.37 SRD5A2 SRD5A1
5 serine-type peptidase activity GO:0008236 9.33 KLK3 KLK2 HPN
6 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 8.96 SRD5A2 SRD5A1
7 cholestenone 5-alpha-reductase activity GO:0047751 8.62 SRD5A2 SRD5A1
Sources

Sources for Prostatic Hyperplasia, Benign

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....